JNJ-26146900
JNJ-26146900 is a selective androgen receptor modulator which was developed by Johnson & Johnson for the potential treatment of prostate cancer but was never marketed.
Description
The drug is a nonsteroidal androgen receptor modulator with mixed agonistic and antagonistic effects. In animals, it partially prevents castration-induced loss of body weight, lean body mass, and bone and reduces prostate weight and prostate tumor growth. The nonsteroidal antiandrogen bicalutamide was also effective in partially preventing castration-induced loss of body weight and lean body mass, suggesting that it too may have some SARM-like activity in certain tissues. However, neither JNJ-26146900 nor bicalutamide were as effective as dihydrotestosterone in terms of these effects. Based on the preceding findings, JNJ-26146900 shows a profile of androgenic and anabolic effects in muscle and bone but antiandrogenic effects in the prostate.The drug is a novel indole derivative SARM and is structurally related to JNJ-37654032.
JNJ-26146900 did not advance past the preclinical research and was never tested in humans. It was first described in the scientific literature by 2007.